| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2e4688cab6da9472ad29a2f050872cc7 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 |
| filingDate |
2003-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2008-03-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_28b8db8693ab3b2651e69914c41b2115
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1d7f03519003f2fe23b66fd5d4c6d968
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_db5c8fb84a7277f98f55b58eff77c4e6 |
| publicationDate |
2008-03-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-7342106-B2 |
| titleOfInvention |
Human antihuman MCP-1 antibody and antibody fragment thereof |
| abstract |
A substance effective for treating immunopathy where MCP-1 is involved is provided. scFv having a high affinity to human MCP-1 was obtained using phage antibody technique. Based on information of VH chain and VL chain obtained from said scFv, a human anti-human MCP-1 antibody and a human anti-human MCP-1 antibody fragment are obtained. Said antibody and antibody fragment are expected to be useful as a medicament for treating inflammation and immunopathy caused by MCP-1. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016025789-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8114964-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009068109-A1 |
| priorityDate |
2002-09-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |